News
Chr. Hansen reports that a new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness.
In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.
Flu-like sickness can take its toll on workforce productivity, health care systems and families with young children, the company notes, and is estimated to have an annual burden on the US economy of $11.2 billion .
According to Chr. Hansen, data from numerous studies already shows a positive correlation between taking certain probiotics and reducing the number of incidents, duration and severity of flu-like sickness. This new study builds upon existing data, to assess the potential health economic impact of probiotics in the US primary care setting. The findings show the significant savings potential taking probiotics can have by reducing the number of sick days, visits to the doctor and prescriptions.
Flu-like sickness is a wide-ranging category including a fever of at least 100°F (37.8°C) and a cough or sore throat. On average over the last five years, there have been 33 million symptomatic cases in the US each year.
“Probiotics are already well established in the healthcare industry, and numerous studies have highlighted the therapeutic potential of specific probiotic strains in helping to maintain a healthy immune system and supporting the defense against harmful bacteria. In addition to the health benefits to an individual, this study demonstrates that taking probiotics also contributes to reducing costs to society and reducing the use of antibiotics. We believe that the impact of probiotics on healthcare will continue to grow in the years to come as we continue to unlock the potential of good bacteria,” said Andrew Scorey, senior vice president, Chr. Hansen Human Health.
Chr. Hansen points out that, according to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security and development today, and it is expected to exceed cancer as the main cause of death by 2050. It is estimated that more than one in three of the antibiotics prescribed to treat flu-like sickness in the US are redundant.
The new study reveals that in the US, some 2.2 million antibiotic courses could be avoided each year if the population takes probiotics.
“We already know that the overuse of antibiotics can cause bacteria to become resistant, meaning current treatments will no longer work. This study provides further evidence of how probiotics and ‘good bacteria’ can respond to some of the world’s biggest challenges,” said Scorey.
The results of the study are published in the journal Frontiers in Pharmacology and were authored and reviewed by independent industry and academic experts. Chr. Hansen sponsored the development of a new simulation model used in the study. The publication title is: Probiotics reduce healthcare cost and societal impact of flu-like respiratory tract infections in the USA: An economic modeling study.
The underlying data used in the study came from two independent reviews: York Health Economics Consortium (YHEC) and Cochrane. The clinical trials in these reviews used 22 probiotic strains, including Chr. Hansen’s Lactobacillus rhamnosus and Bifidobacterium animalis.
“This study builds on independent clinical trials and translates the clinical findings into cost and impact on primary health care. The results present a very strong case for probiotics. At Chr. Hansen, we will continue to build on these findings looking closely into how specific strains can support this health area. As a result of this study, we now have a new simulation model that will provide us with new ways to work with data in future studies,” said Adam Baker, senior manager, Human Health Development at Chr. Hansen.
Chr. Hansen owns some of the world’s best documented probiotic strains. The large number of scientific publications and clinical studies on these strains indicate that they may have beneficial effects on the immune functions.
19 May 2026
Tagatose, a low-calorie, natural sweetener with EU-approved health claims, is now exempt from added sugar labelling in the US – a move that could see uptake scale significantly.
Read more
18 May 2026
US retail giant Walmart has rebranded its flagship ‘Great Value’ range, highlighting the quality and affordability of around 10,000 private label products.
Read more
14 May 2026
Via its Global Strategy 2026-2028, Fairtrade International is calling on the food industry to embed fairer sourcing practices and invest in long-term supplier relationships.
Read more
11 May 2026
Goods are often damaged throughout the supply chain but novel technologies – such as hyperspectral imaging, automated reject systems, and smart indicators – are reducing losses.
Read more
7 May 2026
Protein, gut health, functional beverages, and mental wellbeing are the key health-powered trends driving innovation and growth, says Innova Market Insights.
Read more
7 May 2026
Mondelēz International wants to bolster business further in developed markets, focusing on biscuits in the US and chocolate in Europe, as snacking continues to gain momentum globally, its CEO says.
Read more
5 May 2026
The European front-of-pack nutrition logo, Nutri-Score, is now better aligned with the processed food classification NOVA, following a 2026 algorithm update.
Read more
4 May 2026
The cheapest products contain 2.6 more additives and 21% more sugar than higher-priced products, according to a US study by Harvard and food scanning app Yuka.
Read more
1 May 2026
Global organisation UNICEF has released a best practice toolkit on children’s rights and digital marketing, calling on policymakers and industry to stop unhealthy ads.
Read more
29 Apr 2026
Unibio is forging ahead with plans to open the “world’s largest” single-cell protein plant in Saudi Arabia. “The Middle East conflict has reinforced how critical local food production is,” says its CEO.
Read more